The Emerging Role of CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Emerging Role of CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
Authors
Keywords
-
Journal
Journal of Personalized Medicine
Volume 12, Issue 2, Pages 197
Publisher
MDPI AG
Online
2022-02-01
DOI
10.3390/jpm12020197
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study
- (2021) John Kuruvilla et al. LANCET ONCOLOGY
- Molecular biology of Hodgkin lymphoma
- (2021) Marc A. Weniger et al. LEUKEMIA
- Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma
- (2021) Reid W. Merryman et al. Blood Advances
- Combining AFM13, a bispecific CD30/CD16 antibody, with cytokine-activated cord blood-derived NK cells facilitates CAR-like responses against CD30+ malignancies
- (2021) Lucila N Kerbauy et al. CLINICAL CANCER RESEARCH
- Novel Therapies in the Treatment of Hodgkin Lymphoma
- (2021) Xavier Andrade-Gonzalez et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Cell-programmed nutrient partitioning in the tumour microenvironment
- (2021) Bradley I. Reinfeld et al. NATURE
- Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia
- (2021) Yan-Li Zhao et al. Frontiers in Immunology
- Immune checkpoint inhibitors and allogeneic transplant in lymphoid malignancies: a deceptive friend story
- (2021) Mohammed Al Farttoosi et al. BONE MARROW TRANSPLANTATION
- Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
- (2021) Alison J. Moskowitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Overcoming the breast tumor microenvironment by targeting MDSCs through CAR-T cell therapy.
- (2021) Saisha Abhay Nalawade et al. JOURNAL OF CLINICAL ONCOLOGY
- Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies
- (2021) Razan Mohty et al. Blood Cancer Journal
- Tumor associated antigen specific T cells with nivolumab are safe and persist in vivo in rel/ref Hodgkin Lymphoma
- (2021) Hema Dave et al. Blood Advances
- CD30-Directed CAR-T Cells Co-Expressing CCR4 in Relapsed/Refractory Hodgkin Lymphoma and CD30+ Cutaneous T Cell Lymphoma
- (2021) Natalie S Grover et al. BLOOD
- Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma
- (2021) Timothy J. Voorhees et al. Blood Advances
- Adoptive T-cell therapy for Hodgkin lymphoma
- (2021) Carrie Ho et al. Blood Advances
- Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
- (2020) Enli Liu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exploring the Dilemma of Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy: To Transplant or Not?
- (2020) Stella Bouziana et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cells
- (2020) Marika Guercio et al. HAEMATOLOGICA
- State of the art in CAR T cell therapy for CD19+ B cell malignancies
- (2020) Matthew J. Frigault et al. JOURNAL OF CLINICAL INVESTIGATION
- Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma
- (2020) Carlos A. Ramos et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor-associated macrophages in classical Hodgkin lymphoma: hormetic relationship to outcome
- (2020) Laura Werner et al. Scientific Reports
- Hodgkin lymphoma
- (2020) Joseph M. Connors et al. Nature Reviews Disease Primers
- Co-Expression of IL-7 Improves NKG2D-Based CAR T Cell Therapy on Prostate Cancer by Enhancing the Expansion and Inhibiting the Apoptosis and Exhaustion
- (2020) Cong He et al. Cancers
- Pembrolizumab followed by AVD in untreated early unfavorable and advanced stage classical Hodgkin lymphoma
- (2020) Pamela Blair Allen et al. BLOOD
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
- (2020) Jeremy S Abramson et al. LANCET
- Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial
- (2020) Catherine S Diefenbach et al. Lancet Haematology
- Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
- (2020) Timothy J Voorhees et al. Cancers
- B cells and cancer: To B or not to B?
- (2020) Wolf Herman Fridman et al. JOURNAL OF EXPERIMENTAL MEDICINE
- CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison
- (2020) Peter Dreger et al. Blood Advances
- Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma
- (2020) Layal El Halabi et al. Clinical Lymphoma Myeloma & Leukemia
- IL-15-mediated reduction of mTORC1 activity preserves the stem cell memory phenotype of CAR-T cells and confers superior antitumor activity
- (2019) Darya Alizadeh et al. Cancer Immunology Research
- Challenges of driving CD30-directed CAR-T cells to the clinic
- (2019) Natalie S. Grover et al. BMC CANCER
- An etiological role for the Epstein-Barr virus in the pathogenesis of classical Hodgkin lymphoma
- (2019) Paul G. Murray et al. BLOOD
- Macrophages and Metabolism in the Tumor Microenvironment
- (2019) Ilio Vitale et al. Cell Metabolism
- Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells
- (2019) Ana Cordeiro et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4- positive T-cells that are PD-1-negative
- (2019) Sanjay S. Patel et al. BLOOD
- Retrospective Cohort Study Analyzing the Safety and Efficacy of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
- (2019) Timothy J Voorhees et al. BLOOD
- MDSC Suppression of CAR T Cells Can be Reduced By Targeted Signaling Disruption
- (2019) Estelle V Cervantes et al. BLOOD
- Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors
- (2019) Rachel Grosser et al. CANCER CELL
- Single-Cell Transcriptome Analysis Reveals Disease-Defining T-cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma
- (2019) Tomohiro Aoki et al. Cancer Discovery
- Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients
- (2018) Neha Mehta-Shah et al. BLOOD
- Non-viral RNA chimeric antigen receptor modified T cells in patients with Hodgkin lymphoma
- (2018) Jakub Svoboda et al. BLOOD
- Aerobic Glycolysis Controls Myeloid-Derived Suppressor Cells and Tumor Immunity via a Specific CEBPB Isoform in Triple-Negative Breast Cancer
- (2018) Wei Li et al. Cell Metabolism
- Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma
- (2018) Catherine M. Bollard et al. JOURNAL OF CLINICAL ONCOLOGY
- Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma
- (2018) Joseph M. Connors et al. NEW ENGLAND JOURNAL OF MEDICINE
- LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII
- (2018) Takumi Maruhashi et al. NATURE IMMUNOLOGY
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytes
- (2017) Carlos A. Ramos et al. JOURNAL OF CLINICAL INVESTIGATION
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells
- (2017) Marco Ruella et al. Cancer Discovery
- Targeting Immune System Alterations in Hodgkin Lymphoma
- (2017) Natalie S. Grover et al. Current Hematologic Malignancy Reports
- Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis
- (2016) A Rashidi et al. BONE MARROW TRANSPLANTATION
- Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial
- (2016) Chun-Meng Wang et al. CLINICAL CANCER RESEARCH
- CD58 mutations are common in Hodgkin lymphoma cell lines and loss of CD58 expression in tumor cells occurs in Hodgkin lymphoma patients who relapse
- (2016) F R Abdul Razak et al. GENES AND IMMUNITY
- Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells
- (2016) Omkar U. Kawalekar et al. IMMUNITY
- PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
- (2016) Margaretha G.M. Roemer et al. JOURNAL OF CLINICAL ONCOLOGY
- Role of Cytotoxic Therapy with Hematopoietic Cell Transplantation in the Treatment of Hodgkin Lymphoma: Guidelines from the American Society for Blood and Marrow Transplantation
- (2015) Miguel-Angel Perales et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma
- (2015) A. Rothe et al. BLOOD
- Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Craig H Moskowitz et al. LANCET
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15
- (2014) Y. Xu et al. BLOOD
- Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy
- (2014) Alessandra Romano et al. BRITISH JOURNAL OF HAEMATOLOGY
- IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors
- (2012) N. Cieri et al. BLOOD
- A human memory T cell subset with stem cell–like properties
- (2011) Luca Gattinoni et al. NATURE MEDICINE
- ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned
- (2011) Simonetta Viviani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia
- (2010) Franz Josef Gassner et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Circulating clonotypic B cells in classic Hodgkin lymphoma
- (2009) R. J. Jones et al. BLOOD
- T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model
- (2009) A. Di Stasi et al. BLOOD
- Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma
- (2008) B. Sirohi et al. ANNALS OF ONCOLOGY
- Antitumor Activity of EBV-specific T Lymphocytes Transduced With a Dominant Negative TGF-?? Receptor
- (2008) Aaron E. Foster et al. JOURNAL OF IMMUNOTHERAPY
- Management of Hodgkin Lymphoma in Relapse after Autologous Stem Cell Transplant
- (2008) M. Crump Hematology-American Society of Hematology Education Program
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now